![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 52
2021
Pretzsch, E.; Max, N.; Kirchner, T.; Engel, J.; Werner, J.; Klauschen, F.; Angele, M. K. und Neumann, J.
(2021):
LIN28 promotes tumorigenesis in colorectal cancer but is not associated with metastatic spread.
In: Pathology Research and Practice, Bd. 228, 153669
2020
Ortiz-Brüchle, N.; Muders, M.; Toma, M.; Esposito, I; Hartmann, A.; Stöhr, R.; Reis, H.; Wild, P.; Köllermann, J.; Bremmer, F.; Leichsenring, J.; Stenzinger, A.; Merkelbach-Bruse, S.; Kirfel, S.; Perner, S.; Hartmann, N.; Roth, W.; Jung, A.; Kirchner, T.; Schwamborn, K.; Pfarr, N.; Dahl, E.; Knüchel, R. und Gaisa, N. T.
(2020):
Status der Verfügbarkeit und Anwendung von „next generation sequencing“ (NGS) beim Harnblasenkarzinom – eine Umfrage in der Arbeitsgemeinschaft Uropathologie.
In: Urologe, Bd. 59, Nr. 3: S. 318-325
2019
Westphalen, C. B.; Preinfalk, A.; Krüger, S.; Haas, M.; Renz, B. W.; Riener, M.-O.; Weber, A.; Kirchner, T.; Werner, J.; Heinemann, V; Bergwelt-Baildon, M. von; Baba, H. A.; Siveke, J. T.; Ormanns, S. und Böck, S.
(2019):
Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts.
In: Clinical & Translational Oncology, Bd. 21, Nr. 8: S. 1108-1111
Stintzing, S.; Wirapati, P.; Lenz, H. J.; Neureiter, D.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Kaiser, F.; Al-Batran, S.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Moehler, M.; Scheithauer, W.; Held, S.; Modest, D. P.; Jung, A.; Kirchner, T.; Aderka, D.; Tejpar, S. und Heinemann, V
(2019):
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
In: Annals of Oncology, Bd. 30, Nr. 11: S. 1796-1803
2018
Hirsch, B.; Endris, V.; Lassmann, S.; Weichert, W.; Pfarr, N.; Schirmacher, P.; Kovaleva, V.; Werner, M.; Bonzheim, I.; Fend, F.; Sperveslage, J.; Kaulich, K.; Zacher, A.; Reifenberger, G.; Koehrer, K.; Stepanow, S.; Lerke, S.; Mayr, T.; Aust, D. E.; Baretton, G.; Weidner, S.; Jung, A.; Kirchner, T.; Hansmann, M. L.; Burbat, L.; Wall, E. von der; Dietel, M. und Hummel, M.
(2018):
Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
In: Virchows Archiv, Bd. 472, Nr. 4: S. 557-565
Krüger, S.; Heinemann, V.; Ross, C.; Diehl, F.; Nagel, D.; Ormanns, S.; Liebmann, S.; Prinz-Bravin, I.; Westphalen, C. B.; Haas, M.; Jung, A.; Kirchner, T.; Bergwelt-Baildon, M. von; Böck, S. und Holdenrieder, S.
(2018):
Repeated (mut)KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
In: Annals of Oncology, Bd. 29, Nr. 12: S. 2348-2355
2017
Heppt, M.; Siepmann, T.; Engel, J.; Schubert-Fritschle, G.; Eckel, R.; Mirlach, L.; Kirchner, T.; Jung, A.; Gesierich, A.; Ruzicka, T.; Berking, C. und Flaig, M. J.
(2017):
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
In: Journal Der Deutschen Dermatologischen Gesellschaft, Bd. 15: S. 3
Knösel, T.; Reiter, C.; Schubert-Fritschle, Gabriele; Altendorf-Hofmann, A. und Kirchner, T.
(2017):
Neuroendokrine Neoplasien des Magens: Was ist neu?
In: Pathologe, Bd. 38, Nr. 2: S. 98-104
Stintzing, S.; Miller-Phillips, L.; Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jagenburg, A.; Kirchner, T.; Jung, A. und Heinemann, V.
(2017):
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
In: European Journal of Cancer, Bd. 79: S. 50-60
Röcken, C.; Baretton, G. B.; Kreipe, H. H. und Kirchner, T.
(2017):
Universitäre Pathologie in Deutschland.
In: Pathologe, Bd. 38, Nr. 4: S. 324-329
Stintzing, S.; Price, B.; Knight, L.; McCavigan, A.; Walker, S.; Harkin, P.; Kennedy, R.; Neureiter, D.; Held, S.; Jung, A.; Kirchner, T. und Heinemann, V.
(2017):
Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial.
In: Annals of Oncology, Bd. 28
Böck, S.; Mehraein, Y.; Ormanns, S.; Kruger, S.; Westphalen, C. Benedikt; Haas, M.; Jung, A.; Kirchner, T. und Heinemann, V.
(2017):
Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course.
In: Annals of Oncology, Bd. 28, Nr. 2: S. 438-439
Holch, J. W.; Stintzing, S.; Held, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Kirchner, T.; Einem, J. C. von; Modest, D. P. und Heinemann, V.
(2017):
Right-sided colorectal cancer (RC): response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR).
In: Oncology Research and Treatment, Bd. 40: S. 164-165
Kruger, S.; Ormanns, S.; Rösgen, V.; Legenstein, M.-L.; Haas, M.; Westphalen, C. B.; Düwell, P.; Schnurr, M.; Heinemann, V.; Kirchner, T. und Böck, S.
(2017):
IDO1 expression as biomarker in erlotinib-treated patients with advanced pancreatic cancer: translational results from the AIO-PK0104 phase III trial.
In: Oncology Research and Treatment, Bd. 40: S. 235
Burger, P. J.; Kruger, S.; Jühling, A.; Kapp, M.; Berger, A. W.; Ormanns, S.; Ettrich, T. J.; Waidmann, O.; Steiner, B.; Kunzmann, V.; Abendroth, A.; Sinn, M.; Werner, J.; Kirchner, T.; Heinemann, V. und Böck, S.
(2017):
Isolated pulmonary metastases in pancreatic cancer: preliminary results from the retrospective multi-center AIO-YMO-PAK-0515 study.
In: Oncology Research and Treatment, Bd. 40: S. 236-237
Schneider, L.; Selmansberger, M.; Schüttrumpf, L.; Maihöfer, C.; Pflugradt, U.; Kirchner, T.; Woischke, C.; Belka, C.; Zitzelsberger, H.; Ganswindt, U.; Unger, K. und Hess, J.
(2017):
Subgroups of HPV-positive and HPV-negative head and neck squamous cell carcinoma differing in global copy number changes and prognosis.
In: Strahlentherapie und Onkologie, Bd. 193:
S149-S149
Cidre-Aranaz, F.; Grünewald, T. G. P.; Surdez, D.; García-García, L.; Lázaro, J. Carlos; Kirchner, T.; González-González, L.; Sastre, A.; García-Miguel, P.; López-éerez, S. E.; Monzon, S.; Delattre, O. und Alonso, J.
(2017):
EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
In: Oncogene, Bd. 36, Nr. 6: S. 766-776
2016
Modest, Dominik P.; Ricard, Ingrid; Heinemann, Volker; Hegewisch-Becker, S.; Schmiegel, W.; Porschen, R.; Stintzing, Sebastian; Graeven, U.; Arnold, D.; Fischer von Weikersthal, L.; Giessen-Jung, Clemens; Stahler, A.; Schmoll, H. J.; Jung, A.; Kirchner, T.; Tannapfel, A. und Reinacher-Schick, A.
(September 2016):
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
In: Annals of Oncology, Bd. 27, Nr. 9: S. 1746-1753
[PDF, 410kB]
Michl, M.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Hielscher, J.; Scholz, M.; Mueller, S.; Lerch, M. M.; Modest, D. P.; Kirchner, T.; Jung, A. und Heinemann, V.
(2016):
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro).
In: Annals of Oncology, Bd. 27, Nr. 8: S. 1565-1572
Harder, N.; Athelogou, M.; Hessel, H.; Buchner, A.; Schoenmeyer, R.; Schmidt, G.; Stief, C. G.; Kirchner, T. und Binnig, G.
(2016):
Co-Occurrence Features Characterizing Gland Distribution Patterns as New Prognostic Markers in Prostate Cancer Whole-Slide Images.
In: IEEE ... International Symposium On Biomedical Imaging (ISBI), Bd. 13: S. 807-810
Scheel, A. H.; Dietel, M.; Heukamp, L. C.; Jöhrens, K.; Kirchner, T.; Reu, S.; Rüschoff, J.; Schildhaus, H. U.; Schirmacher, P.; Tiemann, M.; Warth, A.; Weichert, W.; Fischer, R. N.; Wolf, J. und Büttner, R.
(2016):
Prädiktive PD-L1-Immunhistochemie beim nichtkleinzelligen Bronchialkarzinom. Aktueller Stand und Erfahrungen der ersten deutschen Harmonisierungsstudie.
In: Pathologe, Bd. 37, Nr. 6: S. 557-567
Baretton, G.; Dietel, M.; Gaiser, T.; Kirchner, T.; Kreipe, H. H.; Quaas, A.; Röcken, C.; Rüschoff, J.; Tannapfel, A.; Lordick, F.; Al-Batran, S.; Hofheinz, R.; Lorenzen, S.; Moehler, M. und Thuss-Patience, P.
(2016):
HER2-Testung beim Magenkarzinom. Ergebnisse eines deutschen Expertentreffens.
In: Pathologe, Bd. 37, Nr. 4: S. 361-366
Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmueller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Hielscher, J.; Lerch, M.; Scheithauer, W.; Jagenburg, A.; Held, S.; Modest, D.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306).
In: Annals of Oncology, Bd. 27: S. 112
Stahler, A.; Stintzing, S.; Urbischek, M.; Modest, D. P.; Fischer von Weikersthal, L.; Kumbrink, J.; Heinemann, V.; Kirchner, T. und Jung, A.
(2016):
Targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) cell lines - a potential prognostic biomarker in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1).
In: Annals of Oncology, Bd. 27
Stahler, A.; Heinemann, V.; Clemens, G.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2016):
Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3-expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial.
In: Oncology Research and Treatment, Bd. 39: S. 72
Musa, J.; Orth, M. F.; Dallmayer, M.; Baldauf, M.; Pardo, C.; Rotblat, B.; Kirchner, T.; Leprivier, G. und Grünewald, T. G. P.
(2016):
Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.
In: Oncogene, Bd. 35, Nr. 36: S. 4675-4688
Modest, D. P.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
Clinical relevance of subsequent treatment procedures on overall survival in FIRE-3/AIO KRK0306 (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) in patients with KRAS wild-type metastatic colorectal cancer.
In: Oncology Research and Treatment, Bd. 39: S. 11
Lordick, F.; Al-Batran, S. E.; Hofheinz, R. D.; Lorenzen, S.; Thuss-Patience, P.; Baretton, G. B.; Dietel, M.; Gaiser, T.; Kirchner, T.; Kreipe, H. H.; Quaas, A.; Röcken, C.; Rüschoff, J. und Tannapfel, A.
(2016):
HER2-Testung beim Magenkarzinom – Ergebnisse eines deutschen Expertentreffens.
In: Zeitschrift für Gastroenterologie, Bd. 54, Nr. 8: S. 791-796
Woischke, C.; Blaj, C.; Schmidt, E. M.; Lamprecht, S.; Engel, Jutta; Hermeking, H.; Kirchner, T. und Horst, D.
(2016):
CYB5R1 links epithelial-mesenchymal transition and poor prognosis in colorectal cancer.
In: Oncotarget, Bd. 7, Nr. 21: S. 31350-31360
2015
Michl, M.; Heinemann, V.; Jung, A.; Engel, Jutta; Kirchner, T. und Neumann, J.
(2015):
Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system.
In: Pathology, Research and Practice, Bd. 211, Nr. 8: S. 601-609
Michl, M.; Thurmaier, J.; Schubert-Fritschle, Gabriele; Wiedemann, Max; Laubender, Rüdiger P.; Nussler, N. C.; Ruppert, R.; Kleeff, J.; Schepp, W.; Reuter, C.; Lohe, F.; Karthaus, M.; Neumann, J.; Kirchner, T.; Engel, Jutta und Heinemann, V.
(2015):
Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic Factors.
In: Clinical Colorectal Cancer, Bd. 14, Nr. 4: S. 281-290
Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, Alexander; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2015):
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
In: International Journal of Cancer, Bd. 138, Nr. 3: S. 739-746
2014
Boeck, S.; Ormanns, S.; Haas, M.; Bachmann, S.; Laubender, Rüdiger P.; Siveke, J. T.; Jung, A.; Kirchner, T. und Heinemann, V.
(2014):
Translational research in pancreatic cancer: KRAS and beyond.
In: Pancreas, Bd. 43, Nr. 1: S. 150-152
2013
Neumann, J.; Wehweck, L.; Maatz, S.; Engel, Jutta; Kirchner, T. und Jung, A.
(2013):
Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
In: Virchows Archiv, Bd. 463, Nr. 4: S. 509-523
Siemens, H.; Neumann, J.; Jackstadt, R.; Mansmann, Ulrich; Horst, D.; Kirchner, T. und Hermeking, H.
(2013):
Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer.
In: Clinical Cancer Research, Bd. 19, Nr. 3: S. 710-720
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Vehling-Kaiser, U.; Winkelmann, C.; Fischer von Weikersthal, L.; Clemens, M. R.; Gauler, T. C.; Marten, A.; Klein, S.; Kojouharoff, G.; Barner, M.; Geissler, M.; Greten, T. F.; Mansmann, Ulrich; Kirchner, T. und Heinemann, V.
(2013):
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
In: British Journal of Cancer BJC, Bd. 108, Nr. 2: S. 469-476
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Ormanns, S.; Haas, M.; Modest, D. P.; Kirchner, T. und Heinemann, V.
(2013):
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.
In: Journal of Gastroenterology, Bd. 48, Nr. 4: S. 544-548
2012
Neumann, J.; Horst, D.; Kriegl, L.; Maatz, S.; Engel, Jutta; Jung, A. und Kirchner, T.
(2012):
A simple immunohistochemical algorithm predicts the risk of distant metastases in right-sided colon cancer.
In: Histopathology, Bd. 60, Nr. 3: S. 416-426
Modest, D. P.; Jung, A.; Moosmann, N.; Laubender, Rüdiger P.; Giessen, C.; Schulz, C.; Haas, M.; Neumann, J.; Boeck, S.; Kirchner, T.; Heinemann, V. und Stintzing, S.
(2012):
The influence of KRAS- and BRAF-mutations on the efficacy of cetuximab-based 1st-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104 -trial.
In: International Journal of Cancer, Bd. 131, Nr. 4: S. 980-986
Vogler, T.; Kriegl, L.; Horst, D.; Engel, Jutta; Sagebiel, S.; Schaffauer, A. J.; Kirchner, T. und Jung, A.
(2012):
The expression pattern of aldehyde dehydrogenase 1 (ALDH1) is an independent prognostic marker for low survival in colorectal tumors.
In: Experimental and Molecular Pathology, Bd. 92, Nr. 1: S. 111-117
Schäfer, C.; Seeliger, H.; Bader, D. C.; Assmann, G.; Buchner, D.; Guo, Y.; Ziesch, A.; Palagyi, A.; Ochs, S.; Laubender, Rüdiger P.; Jung, A.; de Toni, E. N.; Kirchner, T.; Göke, Burkhard; Bruns, C. und Gallmeier, E.
(2012):
Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
In: Journal of Cellular and Molecular Medicine, Bd. 16, Nr. 8: S. 1776-1791
Engelstaedter, V.; Boda, J.; Volklein, C.; Engel, Jutta; Jeschke, Udo; Kirchner, T. und Mayr, D.
(2012):
Lack of prognostic relevance of Her-2/neu, topoisomerase IIalpha and EGFR in advanced ovarian carcinoma.
In: Experimental and Therapeutic Medicine, Bd. 3, Nr. 5: S. 828-834
Engelstaedter, V.; Schiffers, J.; Kahlert, S.; Mainka, P.; Engel, Jutta; Kirchner, T.; Diebold, J. und Mayr, D.
(2012):
Her-2/neu and topoisomerase IIalpha in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
In: Diagnostic Molecular Pathology, Bd. 21, Nr. 2: S. 77-83
Beji, A.; Horst, D.; Engel, Jutta; Kirchner, T. und Ullrich, A.
(2012):
Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer.
In: Clinical Cancer Research, Bd. 18, Nr. 4: S. 956-968
2011
Modest, D. P.; Stintzing, S.; Laubender, Rüdiger P.; Neumann, J.; Jung, A.; Giessen, C.; Haas, M.; Aubele, P.; Schulz, C.; Boeck, S.; Stemmler, H. J.; Kirchner, T. und Heinemann, V.
(2011):
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
In: Anticancer Drugs, Bd. 22, Nr. 9: S. 913-918
2010
Kriegl, L.; Jung, A.; Engel, Jutta; Jackstadt, R.; Gerbes, A. L.; Gallmeier, E.; Reiche, J. A.; Hermeking, H.; Rizzani, A.; Bruns, C. J.; Kolligs, F. T.; Kirchner, T.; Göke, Burkhard und de Toni, E. N.
(2010):
Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma.
In: Clinical Cancer Research, Bd. 16, Nr. 22: S. 5529-5538
Kriegl, L.; Horst, D.; Engel, Jutta; Reiche, J. A.; Kirchner, T. und Jung, A.
(2010):
LEF1 and TCF4 expression correlate inversely with survival in colorectal cancer.
In: Journal of Translational Medicine, Bd. 8, Nr. 1: S. 123
Nagel, J. M.; Kriegl, L.; Horst, D.; Engel, Jutta; Gautam, S.; Mantzoros, C. S.; Kirchner, T.; Göke, Burkhard und Kolligs, F. T.
(2010):
gamma-Catenin is an independent prognostic marker in early stage colorectal cancer.
In: International Journal of Colorectal Disease, Bd. 25, Nr. 11: S. 1301-1309
2009
Horst, D.; Kriegl, L.; Engel, Jutta; Kirchner, T. und Jung, A.
(2009):
Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer.
In: Cancer Investigation, Bd. 27, Nr. 8: S. 844-850
Horst, D.; Reu, S.; Kriegl, L.; Engel, Jutta; Kirchner, T. und Jung, A.
(2009):
The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer.
In: Cancer, Bd. 115, Nr. 10: S. 2063-2070
Horst, D.; Kriegl, L.; Engel, Jutta; Jung, A. und Kirchner, T.
(2009):
CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.
In: European Journal of Cancer, Bd. 45, Nr. 11: S. 2034-2040
2008
Horst, D.; Kriegl, L.; Engel, Jutta; Kirchner, T. und Jung, A.
(2008):
CD133 expression is an independent prognostic marker for low survival in colorectal cancer.
In: British Journal of Cancer BJC, Bd. 99, Nr. 8: S. 1285-1289